stockrowDENTSPLY SIRONA Inc.
XRAY Healthcare Medical Instruments & Supplies
DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024.
- Revenue
- −7.52%
- EPS
- +99.5%
- Free cash flow
- −18.0%
- Total debt
- −1.59%
Quarter to September 2026, against a year earlier
Follow XRAY
Alert me
DENTSPLY SIRONA Inc. (XRAY) Revenue
DENTSPLY SIRONA Inc.'s revenue for fiscal 2025 was $3.7B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $3.6B. Over the past ten years it has ranged from $2.7B (fiscal 2015) to $4.2B (fiscal 2021); the current reading is higher than 27% of that period. DENTSPLY SIRONA Inc. ranks 13th of 47 Medical Instruments & Supplies companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.7B | (2.98%) |
| FY2024 | $3.8B | (4.34%) |
| FY2023 | $4.0B | 1.10% |
| FY2022 | $3.9B | (7.30%) |
| FY2021 | $4.2B | 26.71% |
| FY2020 | $3.3B | (16.98%) |
| FY2019 | $4.0B | 0.90% |
| FY2018 | $4.0B | (0.19%) |
| FY2017 | $4.0B | 6.62% |
| FY2016 | $3.7B | 40.05% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $836.0M | (6.90%) |
| Jun 2026 | $898.0M | 2.05% |
| Mar 2026 | $880.0M | (8.43%) |
| Dec 2025 | $961.0M | 6.31% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| XRAY DENTSPLY SIRONA Inc. | $3.6B |
| STVN Stevanato Group S.p.A. compare | $1.4B |
| WRBY Warby Parker Inc. compare | $934.7M |
| AZTA Azenta, Inc. compare | $613.8M |
| ATRC AtriCure, Inc. compare | $589.8M |
| STAA STAAR Surgical Company compare | $328.3M |
| LMAT LeMaitre Vascular, Inc. compare | $269.4M |
| KMTS Kestra Medical Technologies, Ltd. compare | $106.7M |
| PLSE Pulse Biosciences, Inc compare | $1.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on XRAY
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement